Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) Income from Continuing Operations (2020 - 2021)

Design Therapeutics' Income from Continuing Operations history spans 2 years, with the latest figure at 11127000.0 for Q4 2021.

  • For Q4 2021, Income from Continuing Operations fell 188.19% year-over-year to 11127000.0; the TTM value through Dec 2021 reached 35831000.0, down 330.14%, while the annual FY2025 figure was 69792000.0, 40.74% down from the prior year.
  • Income from Continuing Operations for Q4 2021 was 11127000.0 at Design Therapeutics, up from 11337000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 623000.0 in Q1 2020 and bottomed at 11337000.0 in Q3 2021.